Vaccination is one of the most effective public health interventions, preventing millions of deaths annually. Vaccines work by presenting antigens to the immune system to generate immunological memory, protecting against future infection.
Types of Vaccines
Several types of vaccines are used in clinical practice. Live-attenuated vaccines contain weakened pathogens that replicate minimally without causing disease; examples include measles-mumps-rubella (MMR), varicella, oral polio (Sabin), yellow fever, and BCG, and they induce strong, long-lasting humoral and cellular immunity. Inactivated (killed) vaccines contain whole pathogens inactivated by heat, chemicals (formalin), or radiation; examples include inactivated polio (Salk), hepatitis A, rabies, and whole-cell pertussis, and they require multiple doses and boosters. Subunit vaccines contain purified antigenic components rather than whole pathogens; examples include hepatitis B (HBsAg), acellular pertussis, HPV (virus-like particles), and influenza (split or subunit). Toxoid vaccines use inactivated bacterial toxins (formalin-treated) that retain immunogenicity; examples include diphtheria and tetanus toxoids, typically combined as DTaP or Tdap. mRNA vaccines deliver mRNA encoding target antigens in lipid nanoparticles; examples include COVID-19 vaccines (Pfizer-BioNTech, Moderna), and they induce strong humoral and cellular responses while being rapidly designed. Viral vector vaccines use harmless viruses (adenovirus, vaccinia) to deliver antigen genes; examples include COVID-19 vaccines (Janssen, AstraZeneca) and the Ebola vaccine (rVSV-ZEBOV).
Immunological Basis
Vaccines induce both humoral (antibody-mediated) and cell-mediated (T cell) immunity. Neutralizing antibodies block pathogen entry, while cytotoxic T cells eliminate infected cells. The primary response occurs after initial vaccination, producing IgM followed by IgG, and memory B and T cells persist for years or decades. Booster doses reactivate memory cells, producing rapid, high-titer antibody responses (secondary response). Herd immunity occurs when a sufficiently high proportion of the population is vaccinated, protecting vulnerable individuals who cannot be vaccinated.
Vaccine Adjuvants
Adjuvants enhance the immune response to antigens, reducing the amount of antigen or number of doses needed. Aluminum salts (alum) are the most widely used adjuvant, promoting depot effect and NLRP3 inflammasome activation. MF59 (oil-in-water emulsion) and AS04 (MPL plus alum) are used in influenza and HPV vaccines respectively. Novel adjuvants include AS01 (liposome-based, used in shingles vaccine), CpG oligonucleotides (TLR9 agonist), and saponin-based Matrix-M.
Vaccine Development and Testing
Vaccine development proceeds through several phases. The preclinical phase involves antigen identification and formulation testing in animal models for immunogenicity and safety. Phase I consists of small human trials (20-100 subjects) assessing safety and dosage. Phase II involves expanded trials (100-1000 subjects) evaluating immunogenicity, dosing schedule, and adverse events. Phase III comprises large-scale efficacy trials (thousands to tens of thousands) comparing vaccine to placebo under real-world conditions.
Herd Immunity and Vaccine Coverage
The herd immunity threshold depends on the basic reproduction number (R0). For measles (R0 = 12-18), approximately 92-95% vaccination coverage is needed. Vaccine hesitancy, driven by misinformation, safety concerns, or religious beliefs, threatens herd immunity and leads to disease resurgence. Mandatory vaccination policies and public education campaigns are used to maintain coverage rates.
Current Challenges
Antigenic variation presents a major challenge: influenza requires annual vaccine updates, and HIV and HCV have proven difficult due to high mutation rates and immune evasion. Waning immunity means some vaccines (pertussis, influenza) require periodic boosters as immunity declines over time. For emerging pathogens, rapid vaccine development platforms (mRNA, viral vectors) enabled COVID-19 vaccines within one year, establishing a paradigm for future pandemic response.
